Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

E Goss, Paul; N Ingle, James; I Pritchard, Kathleen; J Robert, Nicholas; Muss, Hyman; Gralow, Julie; Gelmon, Karen; Whelan, Tim; Strasser-Weippl, Kathrin; Rubin, Sheldon; Sturtz, Keren; C Wolff, Antonio; Winer, Eric; Hudis, Clifford; Stopeck, Alison; Thaddeus Beck, J; S Kaur, Judith; Whelan, Kate; Tu, Dongsheng; R Parulekar, Wendy

doi:10.1056/nejmoa1604700

Public

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Shared by NobleBlocks on Jul 21, 2016 • 12:00 AM UTC

Authors:

Paul E Goss

James N Ingle

Kathleen I Pritchard

Abstract

BACKGROUND: Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years may further reduce the ri...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!